Ritonavir News and Research

RSS
Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Study results in three new co-amorphous drug systems with great anti-COVID-19 potential

Study results in three new co-amorphous drug systems with great anti-COVID-19 potential

Further optimization of cysteine-reactive pyrazoline-based covalent inhibitors for the SARS-CoV-2 Mpro

Further optimization of cysteine-reactive pyrazoline-based covalent inhibitors for the SARS-CoV-2 Mpro

Exploring biomedical literature and clinical trial records to identify new drug combinations for COVID-19 treatment

Exploring biomedical literature and clinical trial records to identify new drug combinations for COVID-19 treatment

WHO experts suggest antiviral drug for patients with non-severe covid-19 at highest risk of hospitalization

WHO experts suggest antiviral drug for patients with non-severe covid-19 at highest risk of hospitalization

Identifying and managing drug-drug interactions key to the safe use of nirmatrelvir–ritonavir in COVID-19 treatment

Identifying and managing drug-drug interactions key to the safe use of nirmatrelvir–ritonavir in COVID-19 treatment

Study explores the decline in viral load and immune response in COVID-19 patients

Study explores the decline in viral load and immune response in COVID-19 patients

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

Trial of early antiviral therapy for COVID-19 shows no significant benefit

Trial of early antiviral therapy for COVID-19 shows no significant benefit

Phase one study of oral SARS-CoV-2 antiviral agent nirmatrelvir

Phase one study of oral SARS-CoV-2 antiviral agent nirmatrelvir

Study uncovers a series of natural products that can inhibit the main protease of SARS-CoV-2

Study uncovers a series of natural products that can inhibit the main protease of SARS-CoV-2

Innate immune processes involved in SARS-CoV-2 recognition and resultant inflammation

Innate immune processes involved in SARS-CoV-2 recognition and resultant inflammation

3C-like protease inhibitor clinical candidate, S-217622, as a treatment for SARS-CoV-2

3C-like protease inhibitor clinical candidate, S-217622, as a treatment for SARS-CoV-2

UK's most vulnerable will soon be able to access second ground-breaking antiviral

UK's most vulnerable will soon be able to access second ground-breaking antiviral

More than 5,000 people enrolled in PANORAMIC study for COVID-19 antivirals

More than 5,000 people enrolled in PANORAMIC study for COVID-19 antivirals

Evaluating the use of megadoses of corticosteroids as a treatment of COVID-19

Evaluating the use of megadoses of corticosteroids as a treatment of COVID-19

Eligible adults urged to take part in world-first COVID-19 study of antivirals

Eligible adults urged to take part in world-first COVID-19 study of antivirals

An algorithm to predict host cleavage targets of SARS-CoV-2 3CLPro

An algorithm to predict host cleavage targets of SARS-CoV-2 3CLPro

PAXLOVID shown to be highly effective against all SARS-CoV-2 variants

PAXLOVID shown to be highly effective against all SARS-CoV-2 variants

Study shows inequalities in addressing post-acute neurological manifestations of COVID-19

Study shows inequalities in addressing post-acute neurological manifestations of COVID-19

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern